Skip to main content
Erschienen in: Endocrine 2/2014

01.06.2014 | Fellows Corner

“Occult” ovarian Leydig cell tumor: when laboratory tells more than imaging

verfasst von: Rosa Maria Paragliola, Francesco Torino, Paola Senes, Laura Castellino, Vanda Salutari, Alfredo Pontecorvi, Giovanni Scambia, Salvatore M. Corsello

Erschienen in: Endocrine | Ausgabe 2/2014

Einloggen, um Zugang zu erhalten

Abstract

Hyperandrogenism is a common finding in premenopausal age and is generally caused by polycystic ovarian syndrome or other benign disease. Androgen-secreting tumors represent only 0.2 % of the causes of hyperandrogenism and usually present with severe clinical features, abrupt onset, and very high androgens levels. We describe here three cases of occult ovarian Leydig cell tumors suspected on the basis of severe clinical features of hyperandrogenism rapidly worsening, with elevated serum total testosterone levels, in which bilateral ovariectomy was performed and tumor was confirmed by post-operative histology. In all three cases, imaging was negative for ovarian tumor. Moreover, in one case the confounding concomitant finding of bilateral adrenal masses posed an additional challenge. Our experience highlights that testosterone levels represent the most helpful marker in the diagnosis of androgen-secreting ovarian tumor. In the absence of imaging findings, bilateral ovariectomy should be indicated, if supported by unequivocal clinical and laboratory data.
Literatur
1.
Zurück zum Zitat R. Azziz, L.A. Sanchez, E.S. Knochenhauer, C. Moran, J. Lazenby, K.C. Stephens, K. Taylor, L.R. Boots, Androgen excess in women: experience with over 1000 consecutive patients. J. Clin. Endocrinol. Metab. 89, 453–462 (2004)PubMedCrossRef R. Azziz, L.A. Sanchez, E.S. Knochenhauer, C. Moran, J. Lazenby, K.C. Stephens, K. Taylor, L.R. Boots, Androgen excess in women: experience with over 1000 consecutive patients. J. Clin. Endocrinol. Metab. 89, 453–462 (2004)PubMedCrossRef
2.
3.
Zurück zum Zitat A.K. Shanbhogue, D.K. Shanbhogue, S.R. Prasad, V.R. Surabhi, N. Fasih, C.O. Menias, Clinical syndromes associated with ovarian neoplasms: a comprehensive review. Radiographics 30, 903–919 (2010)PubMedCrossRef A.K. Shanbhogue, D.K. Shanbhogue, S.R. Prasad, V.R. Surabhi, N. Fasih, C.O. Menias, Clinical syndromes associated with ovarian neoplasms: a comprehensive review. Radiographics 30, 903–919 (2010)PubMedCrossRef
4.
Zurück zum Zitat U. Blume-Peytavi, S. Atkin, J. Shapiro, S. Lavery, R. Grimalt, R. Hoffmann, U. Gieler, A. Messenger, European Consensus on the evaluation of women presenting with excessive hair growth. Eur. J. Dermatol. 19, 597–602 (2009)PubMed U. Blume-Peytavi, S. Atkin, J. Shapiro, S. Lavery, R. Grimalt, R. Hoffmann, U. Gieler, A. Messenger, European Consensus on the evaluation of women presenting with excessive hair growth. Eur. J. Dermatol. 19, 597–602 (2009)PubMed
5.
Zurück zum Zitat E. Carmina, F. Rosato, A. Jannì, M. Rizzo, R.A. Longo, Extensive clinical experience: relative prevalence of different androgen excess disorders in 950 women referred because of clinical hyperandrogenism. J. Clin. Endocrinol. Metab. 91, 2–6 (2006)PubMedCrossRef E. Carmina, F. Rosato, A. Jannì, M. Rizzo, R.A. Longo, Extensive clinical experience: relative prevalence of different androgen excess disorders in 950 women referred because of clinical hyperandrogenism. J. Clin. Endocrinol. Metab. 91, 2–6 (2006)PubMedCrossRef
6.
Zurück zum Zitat E.D. Levens, B.W. Whitcomb, J.M. Csokmay, L.K. Nieman, Selective venous sampling for androgen-producing ovarian pathology. Clin. Endocrinol. (Oxf). 70, 606–614 (2009)PubMedCentralPubMedCrossRef E.D. Levens, B.W. Whitcomb, J.M. Csokmay, L.K. Nieman, Selective venous sampling for androgen-producing ovarian pathology. Clin. Endocrinol. (Oxf). 70, 606–614 (2009)PubMedCentralPubMedCrossRef
7.
Zurück zum Zitat M.S. Rothman, M.E. Wierman, How should postmenopausal androgen excess be evaluated? Clin. Endocrinol. (Oxf). 75, 160–164 (2011)PubMedCrossRef M.S. Rothman, M.E. Wierman, How should postmenopausal androgen excess be evaluated? Clin. Endocrinol. (Oxf). 75, 160–164 (2011)PubMedCrossRef
8.
Zurück zum Zitat W. Rosner, H. Vesper, Toward excellence in testosterone testing: a consensus statement. J. Clin. Endocrinol. Metab. 95, 4542–4548 (2010)PubMedCrossRef W. Rosner, H. Vesper, Toward excellence in testosterone testing: a consensus statement. J. Clin. Endocrinol. Metab. 95, 4542–4548 (2010)PubMedCrossRef
9.
Zurück zum Zitat Practice Committee of the American Society for Reproductive Medicine, The evaluation and treatment of androgen excess. Fertil. Steril. 86, S241–S247 (2006) Practice Committee of the American Society for Reproductive Medicine, The evaluation and treatment of androgen excess. Fertil. Steril. 86, S241–S247 (2006)
10.
Zurück zum Zitat M. Hofland, S. Cosyns, P. De Sutter, C. Bourgain, B. Velkeniers, Leydig cell hyperplasia and Leydig cell tumour in postmenopausal women: report of two cases. Gynecol. Endocrinol. 29, 213–215 (2013)PubMedCrossRef M. Hofland, S. Cosyns, P. De Sutter, C. Bourgain, B. Velkeniers, Leydig cell hyperplasia and Leydig cell tumour in postmenopausal women: report of two cases. Gynecol. Endocrinol. 29, 213–215 (2013)PubMedCrossRef
11.
Zurück zum Zitat F.A. Tavassoli, P. Devillee, Pathology and genetics, tumours of the breast and female genital organs (World Health Organization classification of tumours, Lyon, 2003) F.A. Tavassoli, P. Devillee, Pathology and genetics, tumours of the breast and female genital organs (World Health Organization classification of tumours, Lyon, 2003)
12.
Zurück zum Zitat G. Baiocchi, N. Manci, G. Angeletti, R. Celleno, D. Fratini, G. Gilardi, Pure Leydig cell tumor (hilus cell) of the ovary: a rare cause of virilization after menopause. Gynecol. Obstet. Invest. 44, 141–144 (1997)PubMedCrossRef G. Baiocchi, N. Manci, G. Angeletti, R. Celleno, D. Fratini, G. Gilardi, Pure Leydig cell tumor (hilus cell) of the ovary: a rare cause of virilization after menopause. Gynecol. Obstet. Invest. 44, 141–144 (1997)PubMedCrossRef
13.
Zurück zum Zitat A. Monteagudo, D. Heller, N. Husami, R.U. Levine, R. McCaffrey, I.E. Timor-Tritsch, Ovarian steroid cell tumors: sonographic characteristics. Ultrasound Obstet. Gynecol. 10, 282–288 (1997)PubMedCrossRef A. Monteagudo, D. Heller, N. Husami, R.U. Levine, R. McCaffrey, I.E. Timor-Tritsch, Ovarian steroid cell tumors: sonographic characteristics. Ultrasound Obstet. Gynecol. 10, 282–288 (1997)PubMedCrossRef
14.
Zurück zum Zitat R.K. Klotz, E. Müller-Holzner, S. Fessler, D.U. Reimer, I. Zervomanolakis, B. Seeber, V. Mattle, L. Wildt, Leydig-cell-tumor of the ovary that responded to GnRH-analogue administration—case report and review of the literature. Exp. Clin. Endocrinol. Diabetes 118, 291–297 (2010)PubMedCrossRef R.K. Klotz, E. Müller-Holzner, S. Fessler, D.U. Reimer, I. Zervomanolakis, B. Seeber, V. Mattle, L. Wildt, Leydig-cell-tumor of the ovary that responded to GnRH-analogue administration—case report and review of the literature. Exp. Clin. Endocrinol. Diabetes 118, 291–297 (2010)PubMedCrossRef
15.
Zurück zum Zitat K. Sakamoto, R. Fujimitsu, M. Ida, S. Horiuchi, Y. Hamada, K. Yoshimitsu, MR diagnosis of steroid cell tumor of the ovary: value of chemical shift imaging. Magn. Reson. Med. Sci. 8, 193–195 (2009)PubMedCrossRef K. Sakamoto, R. Fujimitsu, M. Ida, S. Horiuchi, Y. Hamada, K. Yoshimitsu, MR diagnosis of steroid cell tumor of the ovary: value of chemical shift imaging. Magn. Reson. Med. Sci. 8, 193–195 (2009)PubMedCrossRef
16.
Zurück zum Zitat R.D. Dickerson, M.J. Putman, M.E. Black, K.R. Pinto, N.G. Diamond, S. Marynick, A.B. Pinto, Selective ovarian vein sampling to localize a Leydig cell tumor. Fertil. Steril. 84, 218 (2005)PubMedCrossRef R.D. Dickerson, M.J. Putman, M.E. Black, K.R. Pinto, N.G. Diamond, S. Marynick, A.B. Pinto, Selective ovarian vein sampling to localize a Leydig cell tumor. Fertil. Steril. 84, 218 (2005)PubMedCrossRef
17.
Zurück zum Zitat C.J. Petersons, M.G. Burt, The utility of adrenal and ovarian venous sampling in the investigation of androgen-secreting tumours. Intern. Med. J. 41, 69–70 (2011)PubMedCrossRef C.J. Petersons, M.G. Burt, The utility of adrenal and ovarian venous sampling in the investigation of androgen-secreting tumours. Intern. Med. J. 41, 69–70 (2011)PubMedCrossRef
18.
Zurück zum Zitat G.A. Kaltsas, J.J. Mukherjee, B. Kola, A.M. Isidori, J.A. Hanson, J.E. Daie, R. Reznek, J.P. Monson, A.B. Grossman, Is ovarian and adrenal venous catheterization and sampling helpul in the investigation of hyperandrogenic women? Clin. Endocrinol. (Oxf). 59, 34–43 (2003)PubMedCrossRef G.A. Kaltsas, J.J. Mukherjee, B. Kola, A.M. Isidori, J.A. Hanson, J.E. Daie, R. Reznek, J.P. Monson, A.B. Grossman, Is ovarian and adrenal venous catheterization and sampling helpul in the investigation of hyperandrogenic women? Clin. Endocrinol. (Oxf). 59, 34–43 (2003)PubMedCrossRef
19.
Zurück zum Zitat C. Regnier, A. Bennet, D. Malet, T. Guez, M. Plantavid, P. Rochaix, X. Monrozies, J.P. Louvet, P. Caron, Intraoperative testosterone assay for virilizing ovarian tumor topographic assessment: report of a Leydig cell tumor of the ovary in a premenopausal woman with an adrenal incidentaloma. J. Clin. Endocrinol. Metab. 87, 3074–3077 (2002)PubMedCrossRef C. Regnier, A. Bennet, D. Malet, T. Guez, M. Plantavid, P. Rochaix, X. Monrozies, J.P. Louvet, P. Caron, Intraoperative testosterone assay for virilizing ovarian tumor topographic assessment: report of a Leydig cell tumor of the ovary in a premenopausal woman with an adrenal incidentaloma. J. Clin. Endocrinol. Metab. 87, 3074–3077 (2002)PubMedCrossRef
20.
Zurück zum Zitat V. Prassopoulos, F. Laspas, F. Vlachou, R. Efthimiadou, L. Gogou, J. Andreou, Leydig cell tumor of the ovary localised with positron emission tomography/computed tomography. Gynecol. Endocrinol. 27, 837–839 (2011)PubMedCrossRef V. Prassopoulos, F. Laspas, F. Vlachou, R. Efthimiadou, L. Gogou, J. Andreou, Leydig cell tumor of the ovary localised with positron emission tomography/computed tomography. Gynecol. Endocrinol. 27, 837–839 (2011)PubMedCrossRef
21.
Zurück zum Zitat O.A. Sanz, P.R. Martinez, R.T. Guarch, M.J. Goñi, J.L. Alcazar, Bilateral Leydig cell tumour of the ovary: a rare cause of virilization in postmenopausal patient. Maturitas 57, 214–216 (2007)PubMedCrossRef O.A. Sanz, P.R. Martinez, R.T. Guarch, M.J. Goñi, J.L. Alcazar, Bilateral Leydig cell tumour of the ovary: a rare cause of virilization in postmenopausal patient. Maturitas 57, 214–216 (2007)PubMedCrossRef
22.
Zurück zum Zitat T.A. Baramki, A.L. Leddy, J.D. Woodruff, Bilateral hilus cell tumors of the ovary. Obstet. Gynecol. 62, 128–131 (1983)PubMed T.A. Baramki, A.L. Leddy, J.D. Woodruff, Bilateral hilus cell tumors of the ovary. Obstet. Gynecol. 62, 128–131 (1983)PubMed
23.
Zurück zum Zitat M. Marcelino, E. Nobre, J. Conceição, L. Lopes, H. Vilar, M. França Martin, A. Carvalho, S. André, A. Horta, J. De Castro, A rare case of hyperandrogenism: bilateral Leydig cell tumor of the ovary. Acta Med. Port. 23, 113–118 (2010)PubMed M. Marcelino, E. Nobre, J. Conceição, L. Lopes, H. Vilar, M. França Martin, A. Carvalho, S. André, A. Horta, J. De Castro, A rare case of hyperandrogenism: bilateral Leydig cell tumor of the ovary. Acta Med. Port. 23, 113–118 (2010)PubMed
24.
Zurück zum Zitat J. Böhm, M. Röder-Weber, H. Höfler, M. Kolben, Bilateral stromal Leydig cell tumour of the ovary. Case report and literature review. Pathol. Res. Pract. 187, 348–352 (1991)PubMedCrossRef J. Böhm, M. Röder-Weber, H. Höfler, M. Kolben, Bilateral stromal Leydig cell tumour of the ovary. Case report and literature review. Pathol. Res. Pract. 187, 348–352 (1991)PubMedCrossRef
25.
Zurück zum Zitat S. Duun, Bilateral virilizing hilus (Leydig) cell tumors of the ovary. Acta. Obstet. Gynecol. Scand. 73, 76–77 (1994)PubMedCrossRef S. Duun, Bilateral virilizing hilus (Leydig) cell tumors of the ovary. Acta. Obstet. Gynecol. Scand. 73, 76–77 (1994)PubMedCrossRef
Metadaten
Titel
“Occult” ovarian Leydig cell tumor: when laboratory tells more than imaging
verfasst von
Rosa Maria Paragliola
Francesco Torino
Paola Senes
Laura Castellino
Vanda Salutari
Alfredo Pontecorvi
Giovanni Scambia
Salvatore M. Corsello
Publikationsdatum
01.06.2014
Verlag
Springer US
Erschienen in
Endocrine / Ausgabe 2/2014
Print ISSN: 1355-008X
Elektronische ISSN: 1559-0100
DOI
https://doi.org/10.1007/s12020-013-0066-0

Weitere Artikel der Ausgabe 2/2014

Endocrine 2/2014 Zur Ausgabe

Leitlinien kompakt für die Innere Medizin

Mit medbee Pocketcards sicher entscheiden.

Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag

Erhebliches Risiko für Kehlkopfkrebs bei mäßiger Dysplasie

29.05.2024 Larynxkarzinom Nachrichten

Fast ein Viertel der Personen mit mäßig dysplastischen Stimmlippenläsionen entwickelt einen Kehlkopftumor. Solche Personen benötigen daher eine besonders enge ärztliche Überwachung.

Nach Herzinfarkt mit Typ-1-Diabetes schlechtere Karten als mit Typ 2?

29.05.2024 Herzinfarkt Nachrichten

Bei Menschen mit Typ-2-Diabetes sind die Chancen, einen Myokardinfarkt zu überleben, in den letzten 15 Jahren deutlich gestiegen – nicht jedoch bei Betroffenen mit Typ 1.

15% bedauern gewählte Blasenkrebs-Therapie

29.05.2024 Urothelkarzinom Nachrichten

Ob Patienten und Patientinnen mit neu diagnostiziertem Blasenkrebs ein Jahr später Bedauern über die Therapieentscheidung empfinden, wird einer Studie aus England zufolge von der Radikalität und dem Erfolg des Eingriffs beeinflusst.

Costims – das nächste heiße Ding in der Krebstherapie?

28.05.2024 Onkologische Immuntherapie Nachrichten

„Kalte“ Tumoren werden heiß – CD28-kostimulatorische Antikörper sollen dies ermöglichen. Am besten könnten diese in Kombination mit BiTEs und Checkpointhemmern wirken. Erste klinische Studien laufen bereits.

Update Innere Medizin

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.